Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the period 22 December 2024 to 17 January 2025 are set out below:
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
A Matter of Taste: IPONZ Decision Serves Up Important Reminders on Patent Practice
In October 2024, the Intellectual Property Office of New Zealand (IPONZ) issued a decision concerning a patent application by Suntory Holdings Limited (Suntory) relating to the enhancement of sweetness in beverages using specific combinations of high-intensity sweeteners and sodium, while maintaining
Missing the Boat: NZ Court of Appeal Finds Delayed Patent Claims an Abuse of Process
The New Zealand Court of Appeal has handed down its second appeal decision in the long-running dispute between Sealegs International Limited and Anura Limited (formerly Orion Marine Limited) and
Persistence Doesn’t Pay: Federal Court Calls Time on Decade-Long Patent Amendment Battle
In a comprehensive Federal Court judgment, Justice Perram has ruled that pharmaceutical formulations can constitute a “pharmaceutical substance per se” under the Patents Act 1990 (Cth), dismissing Cipla’s
Excipients Welcome: Federal Court Upholds Formulation Patent Extensions
In a comprehensive Federal Court judgment, Justice Perram has ruled that pharmaceutical formulations can constitute a “pharmaceutical substance per se” under the Patents Act 1990 (Cth), dismissing Cipla’s
Whole Hog or Nothing: Federal Court Reinforces Best Method Obligations in Pig Vaccine Patent
The Full Court of the Federal Court of Australia has dismissed Zoetis Services LLC’s (Zoetis) appeal against Justice Rofe’s two decisions upholding Boehringer Ingelheim Animal Health USA’s (Boehringer) opposition to the grant of three patent applications relating to pig vaccines. We reported on Justice Downes’ two decisions
Three’s a Crowd: Federal Court Massages Out LELO’s Extra Expert
In a recent development in the ongoing patent dispute between EIS GmbH (EIS) and LELO Oceania Pty LTD and LELOiAB (LELO), Justice Downes of the Federal Court has ruled on the participation of an expert witness
Return to Sender: Federal Court Rules ‘Last Mile Logistics’ System Unpatentable
In a recent Federal Court decision, Justice Rofe has dismissed an appeal by Dei Gratia Pty Ltd (Dei Gratia) against the Commissioner of Patents’ (the Commissioner) refusal to grant its patent application…
No Stay, No Delay: Federal Court Pushes Long-Running Litigation Forward Despite High Court Horizon
Justice Burley has handed down a decision in a long-running dispute between Otsuka Pharmaceutical Co., Ltd (Otsuka) and Generic Health Pty Ltd (Generic Health), refusing to grant a stay of proceedings pending the delivery of judgment by the High Court in Commonwealth of Australia v Sanofi & Ors (Sanofi).
Pearce IP BioBlast® for the week ending 20 December 2024
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 20 December 2024 are set out below:
Med Tech Giant Handed Largest Penalty Ever Given Under the Therapeutic Goods Act
On 19 September 2024, the Federal Court of Australia delivered judgment ordering Medtronic Australasia Pty Ltd (Medtronic) to pay $22 million in penalties following proceedings bought by the Department of Health in August 2021…
Salt in the Wound: Federal Court Dissolves Novartis’ Patent Claims and Takes Aim at Hypothetical Tasks
On 13 November 2024, Justice Yates of the Federal Court of Australia delivered his decision in the dispute between Novartis AG and Novartis Pharmaceuticals Australia Pty Limited (together, Novartis) and Pharmacor Pty Limited (Pharmacor) regarding patent AU2003206738 entitled “Pharmaceutical compositions comprising valsartan and NEP inhibitors” (the Patent).
Pearce IP BioBlast® for the week ending 13 December 2024
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 December 2024 are set out below:
Lundbeck-Sandoz Saga Continues: Federal Court Determines Historical Licence Scope in Long-Running Patent Litigation
Justice Jackman has delivered the latest decision in the long-running dispute between Lundbeck and Sandoz regarding Lundbeck’s Australian Patent AU1989036295 for the “(+)-enantiomer of citalopram and process for the preparation thereof”.
Pearce IP BioBlast® for the week ending 6 December 2024
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar...
Pearce IP BioBlast® for the week ending 29 November 2024
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar...